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NUCLEIC ACIDS ENCODING SARCOC YSTIS
NE URONA ANTIGEN AND USES THEREOF

Nucleic acid ampli?cation assays (polymerase chain reac
tion; PCR) for S. neurona detection have been developed
based on the S. neurona ribosomal RNA genes (Fenger et al.,

The present application is a continuation of US. utility
patent application Ser. No. 10/369,430, ?led on Feb. 19,

1994; Marsh et al., 1996). These PCR-based assays detect
the presence of S. neurona DNA, and therefore the parasite,
in the horse, so they can provide a de?nitive indication of

2003 now US. Pat. No. 7,056,733, Which claims the bene?t

of priority of US. provisional patent application No. 60/357,

active infection. HoWever, prior to the present invention,

479, ?led Feb. 15, 2002, the disclosures of Which are

these nucleic acid-based tests have been inherently unreli
able. Speci?cally, parasites may be very feW or non-existent

incorporated herein in their entirety by reference.

in a CSF sample, so there Will be feW or no available target

TECHNICAL FIELD

molecules (i.e., parasite genomic DNA) for PCR ampli?ca
tion. More importantly, the general use of PCR for diagnosis

The present invention relates to nucleic acids of Sarco
cyslis neurona. In particular, the present invention relates to
nucleic acids of Sarcocyslis neurona and to nucleic acid
reagents and antibodies for use in methods of detection and

the reliability of PCR, the technique continues to be troubled
by both false positive and false negative results.
The selection of an antigen for development of a diag

prevention of Sarcocyslis neurona infection. More particu
larly, the present invention relates to novel nucleic acid

pathogen is composed of numerous antigenic proteins. Logi

is still suspect. Although measures can be taken to improve

nostic test can be someWhat subjective since any particular

sequences of Sarcocyslis neurona and to utiliZation thereof

including primers, probes, antigen/antibody diagnostic kits,

20

vectors for production of peptides encoding the novel
nucleic acids, and to antigenic proteins and vaccines against

regard, surface antigens of the Coccidia, such as the primary

Sarcocyslis neurona.

BACKGROUND OF THE INVENTION

cally, the target molecule in a diagnostic assay must elicit a
detectable antibody response in the infected animal. In this

25

Sarcocyslis neurona is an apicomplexan parasite that is

surface antigens of Toxoplasma gondii (Handman and Rem
ington, 1980; Sharma et al., 1983) and Neospora caninum
(HoWe et al., 1998), are exceedingly inmunogenic. These
surface antigens have been designated SAGs and SAG
related sequences (SRSs). Signi?cantly, the TgSAGl sur
face antigen of T gondii has been shoWn to protect mice

the primary cause of equine protoZoal myeloencephalitis

against acute toxoplasmosis (BuloW and Boothroyd, 1991),

(EPM; Dubey et al., 1991), Which is a common and debili
tating infectious disease that affects the central nervous

and the NcSAGl (p29) major surface antigen of N. caninum
30

system of horses. S. neurona is related to the human and

animal pathogen Toxoplasma gondii and to the important
veterinary pathogen Neospora spp. The geographic range of

SAGs are at least candidate proteins for the development of

S. neurona appears to be limited to the Western hemisphere,

thus EPM primarily affects horses in the Americas.
De?nitive antemortem diagnosis of EPM remains exceed
ingly dif?cult, for a variety of reasons. Horses a?licted With

35

(i.e., SnSAG2, SnSAG3, and SnSAG4) are effective target
molecules for examining immune responses in infected

neurological disorders (MacKay et al., 2000). Furthermore,

nostic information other than indicating previous exposure
to the parasite. Analysis of cerebrospinal ?uid (CSF) to
reveal intrathecal antibody production has improved the
predictive value of antibody detection for EPM diagnosis.
HoWever, interpretation of CSF antibody presence can be
confounded by contamination of the CSF sample With
minute amounts of serum antibodies (Miller et al., 1999).

horses and for developing improved assays for EPM diag
40

and antibody kits, for fast and reliable diagnosis of S.
neurona infection.
45

an antigenic protein derived from Sarcocyslis neurona, or a
50

thus more reliable, techniques that are more appropriate for
diagnostic use.

unique fragment thereof. In one embodiment, the invention
provides novel isolated nucleic acids encoding membrane
associated polypeptides SnSAG2, SnSAG3, and SnSAG4.

The present invention also provides puri?ed antigenic
polypeptide fragments encoded by the novel nucleic acid
55

sequences set forth herein that encode for Sarcocyslis neu
rona. In one embodiment, the invention provides puri?ed

antigenic proteins or puri?ed antigenic polypeptide frag
ments encoded by the novel nucleic acid sequences set forth
herein that encode for SnSAG2, SnSAG3, and SnSAG4. In
60

another embodiment, the present invention provides a puri

?ed antigenic polypeptide fragment encoded by the nucleic
acid sequences set forth herein or a selective portion thereof,

the immunoblot has been utiliZed for a number of years to

help diagnose EPM, it is a ?rst-generation test that needs to
be replaced With improved assays based on simpli?ed, and

SUMMARY OF THE INVENTION

The present invention satis?es the aforementioned need in
the art by providing a novel isolated nucleic acid encoding

al., 1993; MacKay et al., 2000). Unfortunately, Western blot
analysis is primarily a research tool that is relatively labo
rious and someWhat hindered by subjectivity, so any
improvements to the immunoblot are of limited value. While

nosis. Such molecules Would also provide the basis for

improved vaccines and diagnostic kits, including antigen

Other contemporary diagnostic assays provide only
mediocre predictive value for EPM diagnosis. Western blot
analysis (a.k.a., immunoblot) of crude S. neurona lysate
remains the principal immunodiagnostic test that is used to
detect antibodies in suspect EPM horses (Granstrom et al.,
1993). The assay relies on the recognition of several anti
gens, primarily in the loW molecular Weight range, by
serum/CSF antibodies (Dubey et al., 2001b; Granstrom et

both diagnostic assays and protective vaccines.
Despite the foregoing art, prior to the present invention it
had not been shoWn that the surface antigens of S. neurona

EPM exhibit signs that are similar to a number of different

S. neurona infection does not equate to disease, since only
a small proportion of seropositive horses Will suffer from
EPM (MacKay et al., 2000); as a consequence, the detection
of anti-S. neurona antibodies in serum provides little diag

has been used to develop an ELISA for detection of

Neospora infection in cattle (HoWe et al., 2002). Collec
tively, these previous studies demonstrate that coccidian

65

in a pharmaceutically acceptable carrier.
The present invention also provides isolated nucleic acids
capable of selectively hybridizing With the nucleic acid from
Sarcocyslis neurona including, but not limited to, primers
and probes for utiliZation in polymerase chain reaction
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(PCR) and other nucleic acid ampli?cation techniques. The

FIG. 3 shoWs a Western blot analysis of the SnSAGs in S.
neurona meroZoites. The SnSAG genes Were expressed in E.

isolated nucleic acids of the present invention are capable of

coli, and monospeci?c polyclonal antisera Were generated
against the recombinant proteins. Western blot analysis of
reduced antigen revealed that each SnSAG migrated signi?
cantly higher than its predicted molecular Weight, consistent

hybridizing under conditions of loW, moderate, and high
stringency With a nucleic acid from Sarcocyslis neurona.

Further, the present invention provides vectors compris
ing the isolated nucleic acids, or degenerate variants thereof,

With What has been observed for the T gondii SAGs/SRS.
SnSAG1 and SnSAG4 co-migrated and corresponded to the

set forth herein encoding Sarcocyslis neurona or a unique

fragment thereof and provides the vector in a host capable of

expressing the polypeptide encoded by that nucleic acid.

immunodominant band at about 30-32 kDa. SnSAG2 cor

Still yet further, the present invention also provides a
puri?ed polyclonal and or a monoclonal antibody speci?

responded to an immunodominant band at approximately
18-20 kDa.

cally reactive With Sarcocyslis neurona and a method of
detection of Sarcocyslis neurona utiliZing the antibodies of
the present invention.

Sarcocyslis neurona meroZites. Triton X-114 partitioning

FIG. 4 shoWs the SnSAGs are membrane-associated in
assays indicated that the SnSAGs are associated With mem

branes, consistent With their surface localiZation via gly

The above-described embodiments provided by the
present invention, provide a method for detecting Sarcocys
Zis neurona in a biological sample, comprising detecting the
presence in the sample of an antibody or fragment thereof
Which speci?cally binds to a polypeptide comprising an
isolated amino acid sequence selected from the group set

colipid anchoring. Western blot analysis of the partitioned
proteins With the SnSAG-speci?c polyclonal antisera
revealed that all four SnSAGs Were separated exclusively

into the detergent phase (D). The control protein, SnMIClO,
20

Was partitioned into the aqueous phase (A), as expected.
FIG. 5 shoWs that the four SnSAGs are displayed on the

forth in the Sequence Listing as SEQ ID NO.: 24, SEQ ID
NO: 26, and SEQ ID NO: 28. In one embodiment of the

surface of Sarcocyslis neurona meroZoites. Surface biotiny

method, the biological sample is serum. In another embodi

lation of S. neurona meroZoites indicated that the four
SnSAGs are displayed on the surface of the parasite. West

ment, the present invention provides a method as described

ern blot analysis With the SnSAG-speci?c antisera revealed
each of the SnSAGs in the biotinylated protein fraction

for detecting Sarcocyslis neurona in cerebrospinal ?uid

(CSF).

precipitated With immobiliZed streptavidin. The SnSAGs

Finally, the present invention provides a kit for detecting
Sarcocyslis neurona in a biological sample, comprising at
least one isolated amino acid sequence selected from the

group set forth in the Sequence Listing as SEQ ID NO.: 24,
SEQ ID NO: 26, and SEQ ID NO: 28, and a reporter
molecule for detecting a ?rst antibody or fragment thereof
Which speci?cally binds to a polypeptide comprising the at
least one isolated amino acid sequence. The reporter mol
ecule may be any suitable detectable second antibody or

40

Were not present in the non-labeled parasites, thus indicating
that the streptavidin precipitation Were speci?c for biotin
labeled proteins. The negative control protein (actin) Was not
detected in the biotin-labeled/streptavidin-precipitated pro
tein fraction.
FIG. 6 shoWs reciprocal antibody titers in serum of
EPM-con?rmed horses, determined by an ELISA using the
recombinant surface antigens of the present invention.
FIG. 7 shoWs reciprocal antibody titers in CSF of EPM
con?rmed horses, determined by an ELISA using the recom
binant surface antigens of the present invention.
FIG. 8 shoWs expression of S. neurona surface antigens in

45

DETAILED DESCRIPTION OF THE
INVENTION

30

35

fragment thereof Which binds to the ?rst antibody or frag
ment thereof, and Which is labeled With a detectable moiety
or bound to a substrate.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a sequence comparison of mature SnSAG1,
SnSAG3, and SnSAG4 With TgSAG2E. The S. neurona
surface antigens SnSAG1, SnSAG3 and SnSAG4 are most

COS-1 (green monkey kidney) cells, detected by immunof
luorescent labeling With ?uorescein isothiocyanate.

similar to the TgSAG2 family of T gondi surface antigens.
The sequences presented in the Figure are for the mature

The present invention may be understood more readily by
reference to the folloWing detailed description of speci?c

proteins after cleaving off the N-terminal signal peptide and
the C-terminal signal for the GPI anchor. Sequence align
ments of the predicted mature proteins revealed very mod

embodiments and the examples included therein. As used in
50 the claims, “a” can mean one or more. As can be appreciated

erate sequence identity (<25%). HoWever, the SnSAGs
contain 10/12 conserved cysteine residues that have been
observed previously, suggesting that the SnSAGs have a
tertiary structure that is similar to What has been determined

for the TgSAGs/SRSs.

by one of skill in the art, methods and materials similar or
equivalent to those described herein can be used in the

practice of the present invention. All publications, patent
applications, patents, and other references mentioned herein
55

are incorporated by reference in their entirety in order to
more fully describe the state of the art to Which this

FIG. 2 is a sequence comparison of mature SnSAG2 With

TgSAG1 and TgSRS2. The sequences presented in the

invention pertains. It is noted that the abbreviated citations

Figure are for the mature proteins after cleaving off the

of literature referenced herein are set forth fully in US.

Similar to the other SnSAGs, SnSAG2 shares modest

patent application Ser. No. 10/369,430, the disclosure of
Which is also incorporated herein in its entirety by reference.
Although the present invention has been described With
reference to speci?c details of certain embodiments thereof,

sequence identity to its TgSAG orthologues, but contains 6/6
conserved cysteine residues that have been observed in each
half of the prototypical tWo-domain apicomplexan SAG.
SnSAG2 Will also align With the carboxyl-terminal domain

it is not intended that such details should be regarded as
limitations upon the scope of the invention except as and to
the extent that they are included in the accompanying
claims. In the case of a con?ict With incorporated references,

N-terminal signal peptide and the C-terminal signal for the
GPI anchor. The S. neurona surface antigen SnSAG2 is most

60

similar to the TgSAG1 family of T gondii surface antigens.

of the TgSAGs.

65

the present speci?cation, including de?nitions, Will control.
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In addition, the particular embodiments discussed below are
illustrative only and not intended to be limiting.
The present invention satis?es the long felt need in the art

Sequence Listing as SEQ ID NO: 30. As used herein, the
terms “polypeptide” and “protein” are used interchangeably

by providing novel isolated nucleic acid sequences Which
encode antigenic proteins derived from Sarcocyslis neurona,
or Which encode unique antigenic protein fragments thereof.

acids, regardless of length or post-translational modi?cation,
e.g., glycosylation or phosphorylation. By “puri?ed”

and are meant to include any peptide-linked chain of amino

polypeptide is meant a polypeptide that has been substan
tially separated or isolated aWay from other polypeptides in

As used herein, a “nucleic acid” means a chain of at least
tWo or more nucleotides such as DNA (deoxyribonucleic

a cell, organism, or mixture in Which the polypeptide occurs.
Similar to other members of the Apicomplexa, S. neurona
is an obligate intracellular pathogen that utilizes a number of

acid) or RNA (ribonucleic acid). As used herein, a “puri?ed”
nucleic acid is one that is substantially separated from other

nucleic acids found in the naturally-occurring organism. The

unique structures and molecules (i.e., virulence factors) to
support its parasitic lifestyle. Parasite surface molecules are
virulence factors that are typically novel and undoubtedly
important since they are responsible for the initial interac

nucleic acids of the present invention can include positive

tions With the host cell surface and host immune response.

and negative strand RNA as Well as DNA. The above terms

In Toxoplasma gondii, for example, an extensive family of

nucleic acid sequences in a cell or organism in Which the

nucleic acid naturally occurs. Likewise, by “isolated”
nucleic acid is meant separated from at least some of other

encompass double-stranded DNA, single-stranded DNA,

25+ surface antigens has been identi?ed, Which are devel

and RNA and are meant to include genomic and subgenomic

opmentally regulated and exhibit various levels of sequence
similarity to either of the major T gondii surface antigens

nucleic acids found in the naturally-occurring Sarcocyslis
neurona organism. The nucleic acids contemplated by the

20

present invention include a nucleic acid having sequences
from Which a Sarcocyslis neurona cDNA can be transcribed;

or allelic variants and/or homologs of thereof. By “capable
of selectively hybridizing” is meant a sequence Which does
not hybridize With other nucleic acids to prevent an adequate

25

positive hybridization With nucleic acids from Sarcocyslis
neurona and is meant to include stringent hybridization

conditions including loW, moderate and high stringency
conditions. Such stringency conditions are knoWn in the art,
e.g., in US Patent Publication No.: 2002/0115828 A1. By
“unique fragment” is meant a fragment of the nucleic acids

parasitic surface antigens. A sequencing project Was con
30

set forth in the Sequence Listing that is less than the full
length that can selectively hybridize With a RNA, DNA or
cDNA sequence derived from the novel sequences set forth
herein or that can selectively hybridize With nucleic acids
from Sarcocyslis neurona. Modi?cations to the nucleic acids
of the invention are also contemplated as long as the
essential structure and function of the polypeptide encoded

35

40

enough complementary bases exist for selective hybridiza
tion (Kunkel et al. Methods Enzmol. 1987: 154-367, 1987).

SAG/SRS family of surface proteins in T gondii. Each
protein is predicted to contain an amino-terminal signal
peptide and a carboxyl-terminal glycolipid anchor addition
site, indicating surface localization, and Triton X-114 par
titioning and surface biotinylation assays con?rmed that all
four proteins are membrane-associated and displayed on the
S. neurona merozoite surface (See, FIGS. 4 and 5). Addi
tionally, these novel S. neurona proteins possess multiple
conserved cysteine residues that have been described pre

viously for T gondii SAGs and Which are likely important
for the tertiary structure of the proteins (See, FIGS. 1 and 2).

As one of skill in the art can appreciate, there can be

naturally occurring allelic variants and non-naturally occur
ring variants or modi?cations of the nucleic acids of the

ducted that generated approximately 8500 expressed
sequence tags (ESTs) from this organism. Examination of
this sequence database has revealed a family of at least four
S. neurona surface antigens that are orthologues of the

by the nucleic acids is maintained. Likewise, fragments used
as primers or probes can have substitutions so long as

TgSAG1 or TgSAG2. These surface molecules appear to be
involved in receptor/ligand interactions With the host cell
surface, and there is increasing evidence that some of the T
gondii SAGs are involved in modulation of host immune
responses.
In one embodiment, the present invention provides iden
tity and characterization of certain of the virulence factors of
S. neurona. In particular, the present invention provides four
isolated nucleic acids of S. neurona (genes) that encode

45

Due to their surface localization and relative homology to T

invention. For example, homologs or naturally occurring

gondii surface antigens, these S. neurona proteins have been

allelic variants of the nucleic acids of the invention having

designated SnSAG1, SnSAG2, SnSAG3, and SnSAG4.

from about 50% and up to about 99% sequence identity are

Accordingly, one embodiment of the present invention

contemplated by the invention. LikeWise, it is contemplated

comprises an isolated nucleic acid as set forth in the

that non-naturally occurring variants or modi?cations of the

50

nucleic acids of the invention can range from about 50% to
about 99% sequence identity to native S. neurona are

Sequence listing as SEQ ID NO: 21. The nucleic acid
identi?ed in SEQ ID NO: 21 comprises an 828-nucleotide
open reading frame of the SnSAGl gene of Sarcocyslis

contemplated.

neurona Which encodes a 276 amino acid polypeptide set

In particular, one embodiment of the present invention
provides isolated nucleic acids derived from three Sarco
cyslis neurona cluster sequences, namely Sn Cluster 144, Sn
Cluster 21 and Sn Cluster 4, Which comprise the nucleotide
sequences set forth in the Sequence Listing as SEQ ID NOS:

forth in the Sequence Listing as SEQ ID NO: 22. The
polypeptide encoded by SEQ ID NO: 22 has a predicted

1, 3, and 29 respectively and the sequences complimentary
thereto. Also provided by the invention are the correspond
ing protein or polypeptide amino acid sequences for these
three Sarcocyslis neurona cluster sequences. The polypep

55

amino-terminal signal peptide (indicating expression via the
secretory pathWay) and a glycolipid anchor addition site at

the carboxy-terminal end (indicating surface localization).
Database searches With the predicted protein sequence of
60

SnSAGl (rSnSAGl) revealed signi?cant similarity (align
ment score:80, E value:2><10—14) to a 31 kDa surface

antigen from Sarcocyslis muris.

tide sequence comprising Sn Cluster 144 is set forth in the

A recombinant form of the Sarcocyslis neurona SnSAGl

Sequence Listing as SEQ ID NO: 2. The polypeptide
Sequence Listing as SEQ ID NO: 4 and the polypeptide

(rSnSAGl) has been expressed in E. coli. Western blot
analysis of rSnSAGl demonstrated that the recombinant
antigen is recognized by antiserum from a rabbit that Was

sequence comprising Sn Cluster 4 is set forth in the

immunized With S. neurona merozoites and by antibodies in

sequence comprising Sn Cluster 21 is set forth in the

65
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cerebrospinal ?uid (CSF) from an EPM (Sarcocyslis neu
rona infected) horse (See, e.g., FIG. 3).
Another embodiment of the present invention comprises
an isolated nucleic acid as set forth in the Sequence listing
as SEQ ID NO: 23. The nucleic acid identi?ed in SEQ ID
NO: 23 comprises an 975 nucleotide open reading frame of

the invention comprises the polypeptide sequence encoded
by SnGFla set forth in the Sequence Listing as SEQ ID NO:
6.

Another embodiment of the present invention provides an

isolated nucleic acid designated SnGFlb Which comprises

the SnSAG2 gene of Sarcocyslis neurona Which encodes a

the nucleic acid set forth in SEQ ID NO: 7 and sequences
complimentary thereto. Another embodiment of the inven

168 amino acid polypeptide set forth in the Sequence Listing

tion comprises the polypeptide sequence encoded by

as SEQ ID NO: 24.

SnGFlb set forth in the Sequence Listing as SEQ ID NO: 8.
Yet another embodiment of the present invention provides

The present invention also provides an isolated nucleic
acid as set forth in the Sequence listing as SEQ ID NO: 25.
The nucleic acid identi?ed in SEQ ID NO: 25 comprises an
1585 nucleotide open reading frame of the SnSAG3 gene of

an isolated nucleic acid designated SnGFlc Which com

prises the nucleic acid set forth in SEQ ID NO: 9 and
sequences complimentary thereto. Another embodiment of

polypeptide set forth in the Sequence Listing as SEQ ID NO:

the invention comprises the polypeptide sequence encoded
by SnGFlc set forth in the Sequence Listing as SEQ ID NO:

26.

10.

Also provided by the present invention is an isolated
nucleic acid as set forth in the Sequence listing as SEQ ID
NO: 27. The nucleic acid identi?ed in SEQ ID NO: 27
comprises an 1111 nucleotide open reading frame of the

Still another embodiment of the present invention pro
vides an isolated nucleic acid designated SnGFld Which
comprises the nucleic acid set forth in SEQ ID NO: 11 and
sequences complimentary thereto. Another embodiment of

Sarcocyslis neurona Which encodes a 281 amino acid

20

the invention comprises the polypeptide sequence encoded
by SnGFld set forth in the Sequence Listing as SEQ ID NO:

SnSAG4 gene of Sarcocyslis neurona Which encodes a 287

amino acid polypeptide set forth in the Sequence Listing as
SEQ ID NO: 28.
As set forth more fully beloW, these genes have been
expressed as recombinant proteins in E. coli. The recombi
nant SnSAG proteins can be implemented into antibody
capture ELISAs and used to detect the presence of S.

12.

The present invention also provides an isolated nucleic
25

neurona antibodies in a sample. Likewise, the recombinant

proteins provided by the invention can be used as reagents
for use in vaccines against S. neurona.

30

Another embodiment of the present invention provides an

isolated nucleic acid designated SnGFlf Which comprises
the nucleic acid set forth in SEQ ID NO: 15 and sequences
complimentary thereto. Another embodiment of the inven
tion comprises the polypeptide sequence encoded by

Another embodiment of the present invention includes the

discovery of additional novel expressed sequence tags (EST)
that encode novel antigenic peptides for utiliZation in the
vaccines and diagnostic kits as disclosed by this invention.
In particular, cluster analysis of the Sarcocyslis neurona

acid designated SnGFle Which comprises the nucleic acid
set forth in SEQ ID NO: 13 and sequences complimentary
thereto. Another embodiment of the invention comprises the
polypeptide sequence encoded by SnGFle set forth in the
Sequence Listing as SEQ ID NO: 14.

35

SnGFlf set forth in the Sequence Listing as SEQ ID NO: 16.
Yet another embodiment of the present invention provides

expressed sequence tags (ESTs) generated from the cSn.l

an isolated nucleic acid designated SnGFl g Which com

cDNA library has revealed a gene family that encodes at

prises the nucleic acid set forth in SEQ ID NO: 17 and
sequences complimentary thereto. Another embodiment of

least eight homologous proteins. Of the approximately 8500
S. neurona ESTs that have been generated thus far, roughly
540 sequences can be placed in this gene family, Which has
been provisionally designated SnGFl (S. neurona Gene
Family 1). Based on its relative abundance in the collection

40

18.

of S. neurona ESTs, SnGFl encodes a set of similar proteins

(at least eight) that are highly expressed and most likely play
signi?cant roles in the biology of S. neurona (i.e., parasite
virulence factors). In addition to their biological importance,
the abundance of these proteins Would suggest that they
elicit signi?cant immune responses in infected animals.
Collectively, the characteristics of the novel nucleic acids of
SnGFl, and the encoded proteins therefrom, make this gene

45

20.
50

family Well suited for the development of improved diag

55

proteins of, e.g., 109 amino acids, 106 amino acids, and 107
amino acids in length, and the proteins share approximately

derived therefrom Which can be utiliZed to diagnose and
prevent infection of S. neurona. Puri?ed polypeptides
encoded by the nucleic acids are also provided. These
polypeptides can be utiliZed in methods of diagnosis or as
vaccine components for prevention of infection. Vectors are
present invention. The vectors can be utiliZed in host expres

predicted N-terminal signal peptide and a predicted trans
60

bers shoW no similarity to sequences in the current public

gene databases, suggesting that SnGFl is relatively unique

sion systems to produce antigenic peptide reagents for
diagnostic and prophylactic applications. The present inven
tion also provides puri?ed antibodies selectively reactive
With S. neurona. These antibodies can be used in various
diagnostic methods or as a therapeutic.

to S. neurona.

Accordingly, one embodiment of the present invention
provides an isolated nucleic acid designated SnGFla Which
comprises the nucleic acid set forth in SEQ ID NO: 5 and
sequences complimentary thereto. Another embodiment of

The present invention provides isolated nucleic acids as
set forth in the Sequence Listing and nucleic acid reagents

also provided Which comprise the nucleic acids of the

70% to 80% sequence identity. These proteins have a
membrane domain near the C-terminus. The SnGFl mem

Still another embodiment of the present invention pro
vides an isolated nucleic acid designated SnGFl h Which
comprises the nucleic acid set forth in SEQ ID NO: 19 and

sequences complimentary thereto. Another embodiment of
the invention comprises the polypeptide sequence encoded
by SnGFl h set forth in the Sequence Listing as SEQ ID NO:

nostics and/or vaccines for EPM as set forth herein.

The eight SnGFl isoforms identi?ed thus far have been
designated SnGFla-h. These genes are predicted to encode

the invention comprises the polypeptide sequence encoded
by SnGFl g set forth in the Sequence Listing as SEQ ID NO:

65

In one embodiment, the invention provides puri?ed anti
genic polypeptides encoded by the nucleic acids set forth in
the Sequence Listing. The invention also provides these

antigenic polypeptides in a pharmaceutically acceptable

US 7,256,282 B2
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exposed to the parasite to test the potential vaccine effect of

carrier. The amino acid sequence of these polypeptides can
be deduced from the nucleotide sequences set forth in the

the speci?c immunogenic fragment. The speci?city of a
putative immunogenic fragment can be ascertained by test

Sequence Listing.
Puri?ed antigenic polypeptide fragments encoded by the

ing sera, other ?uids or lymphocytes from the inoculated
animal for cross reactivity With other closely related Sarco

nucleic acids of the present invention are also contemplated.
As used herein, “puri?ed” means the antigen is at least
su?iciently free of contaminants or cell components With

cyslis spp.

Which the antigen normally occurs to distinguish the antigen

invention is also provided. The vectors of the invention can

from the contaminants or components. Puri?ed antigenic
polypeptides of S. neurona and antigenic fragments thereof

be in a host capable of expressing the antigenic polypeptide
fragments contemplated by the present invention. There are

of the present invention are also referred to herein as “the

numerous E. coli expression vectors knoWn to one of

antigen” or “the S. neurona antigen.” It is contemplated that
the antigenic fragments can be encoded from any portion of

the open reading frames set forth in SEQ ID NOS: 24, 26

ordinary skill in the art useful for the expression of the
antigen. Other microbial hosts suitable for use include
bacilli, such as Bacillus sublilis, and other enlerobacleri
aceae, such as Salmonella, Serralia, and various Pseudomo
nas species. In these prokaryotic hosts one can also make

and 28 as described herein. Speci?cally, one example pro

expression vectors, Which Will typically contain expression

vides an approximately 12 kDa antigenic polypeptide
encoded by an open reading frame of SEQ ID NO: 24
consisting essentially of the amino acids encoded by the

control sequences compatible With the host cell (e.g., an
origin of replication). In addition, any number of a variety of

A vector comprising the nucleic acids of the present

the nucleic acid encoding S. neurona as set forth in the

Sequence Listing, but especially-from fragments encoded by

20

Well-known promoters can be present, such as the lactose

nucleotide as sequence set forth in the Sequence Listing as

promoter system, a tryptophan (Trp) promoter system, a

SEQ ID NO: 23.
An antigenic fragment of the antigen can be isolated from
the Whole antigen by chemical or mechanical disruption.
The puri?ed fragments thus obtained can be tested to

beta-lactamase promoter system, or a promoter system from

phage lambda. The promoters Will typically control expres
25

determine their antigenicity and speci?city by the methods
taught herein. Antigenic fragments of the antigen can also be
synthesiZed directly. An immunoreactive fragment is gen

Also, the carboxyterrniinal extension of the antigenic frag

erally an amino acid sequence of at least about ?ve con

secutive amino acids derived from the antigen amino acid

sion, optionally With an operator sequence, and have ribo
some binding site sequences for example, for initiating and
completing transcription and translation. If necessary, for
example, an amino terminal methionine can be provided by
insertion of a Met codon 5' and in-frame With the antigen.

30

ments can be removed using standard oligonucleotide

sequence.

mutagenesis procedures.

The polypeptide fragments of the present invention can
also be recombinant proteins obtained by cloning nucleic
acids encoding the polypeptide in an expression system

several advantages to yeast expression systems. First, evi

capable of producing the antigenic polypeptide or fragments

Additionally, yeast expression can be used. There are

35

dence exists that proteins produced in a yeast secretion
systems exhibit correct disul?de pairing. Second, post

translational glycosylation is ef?ciently carried out by yeast

thereof.

Once the amino acid sequence of the antigen is provided,

secretory systems. In one example, the Saccharomyces cer

it is also possible to synthesiZe, using standard peptide
synthesis techniques, peptide fragments chosen to be
homologous to immunoreactive regions of the antigen and to
modify these fragments by inclusion, deletion or modi?ca

evisiae pre-pro-alpha-factor leader region (encoded by the
40

pre-pro-alpha-factor contains a signal peptide and a pro
segment Which includes a recognition sequence for a yeast
protease encoded by the KEX2 gene: this enZyme cleaves
the precursor protein on the carboxyl side of a Lys-Arg

tion of particular amino acids residues in the derived
sequences. Thus, synthesis or puri?cation of an extremely

large number of peptides derived from the antigen is pos
sible.
The amino acid sequences of the present polypeptides can
contain an immunoreactive portion of the S. neurona antigen
attached to sequences designed to provide for some addi
tional property, such as solubility. The amino acid sequences

45

amino acid to provide for some additional property, such as

60

of antibodies or cell mediated immunity) of an animal to

each concentration is determined. The amounts of antigen

pig, the condition of the subject, the siZe of the subject, etc.
Thereafter an animal so inoculated With the antigen can be

codon Which is folloWed by transcription termination sig
nals. Alternatively, the antigen coding sequences can be
.beta.-galactosidase, used to facilitate puri?cation of the

55

noreactivity, immunogenicity, etc.

administered depend on the subject, eg a horse or a guinea

leader region. This construct is then put under the control of
a strong transcription promoter, such as the alcohol dehy
drogenase I promoter or a glycolytic promoter. The antigen
coding sequence is folloWed by a translation termination

fused to a second protein coding sequence, such as Sj26 or

peptide should posses a bioactive property, such as immu

The puri?ed polypeptide fragments thus obtained can be
tested to determine their immunogenicity and speci?city.
Brie?y, various concentrations of a putative immunogeni
cally speci?c fragment are prepared and administered to an
animal and the immunological response (e.g., the production

dipeptide cleavage-signal sequence. The antigen coding
sequence can be fused in-frame to the pre-pro-alpha-factor

of an S. neurona antigen can include sequences in Which one 50
or more amino acids have been substituted With another

to remove/add amino acids capable of disul?de bonding, to
increase its bio-longevity, alter enzymatic activity, or alter
interactions, e.g., With gastric acidity. In any case, the

MF.alpha.-l gene) is routinely used to direct protein secre
tion from yeast (Brake et al.,l984). The leader region of

65

fusion protein by af?nity chromatography. The insertion of
protease cleavage sites to separate the components of the
fusion protein is applicable to constructs used for expression
in yeast.
Mammalian cells permit the expression of proteins in an
environment that favors important post-translational modi
?cations such as folding and cysteine pairing, addition of
complex carbohydrate structures, and secretion of active
protein. Vectors useful for the expression of antigen in
mammalian cells are characterized by insertion of the anti
gen coding sequence betWeen a strong viral promoter and a
polyadenylation signal. The vectors can contain genes con
ferring either gentamicin or methotrexate resistance for use

US 7,256,282 B2
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as selectable markers. The antigen and immunoreactive
fragment coding sequence can be introduced into a Chinese
hamster ovary cell line using a methotrexate resistance
encoding vector. Presence of the vector DNA in transformed

one speci?ed, in this case, S. neurona. Antibodies can be

made as described in the Examples (see also, HarloW and

Lane, Antibodies; A Laboratory Manual, Cold Spring Har
bor Laboratory, Cold Spring Harbor, N.Y., 1988). Brie?y

cells can be con?rmed by Southern analysis and production

puri?ed antigen can be injected into an animal in an amount
and in intervals sufficient to elicit an immune response.
Antibodies can either be puri?ed directly, or spleen cells can
be obtained from the animal. The cells are then fused With
an immortal cell line and screened for antibody secretion.

of a cDNA or opposite strand RNA corresponding to the

antigen coding sequence can be con?rmed by northern
analysis. A number of other suitable host cell lines capable
of secreting intact proteins have been developed in the art,
and include the CHO cell lines, HeLa cells, myeloma cell
lines, Jurkat cells, etc. Expression vectors for these cells can

The antibodies can be used to screen clone libraries for cells

secreting the antigen. Those positive clones can then be

include expression control sequences, such as an origin of
replication, a promoter, an enhancer, and necessary infor

sequenced (see, for example, Kelly et al., Bio/Technology,
10: 163-167, (1992) and Bebbington et at., Bio/Technology,
10: 169-175, (1992).

mation processing sites, such as ribosome binding sites,

RNA splice sites, polyadenylation sites, and transcriptional

The antibody can be bound to a substrate or labeled With
a detectable moiety or both bound and labeled. The detect

terminator sequences. Preferred expression control
sequences are promoters derived from immunoglobulin
genes, SV40, Adenovirus, Bovine Papilloma Virus, etc. The

able moieties contemplated by the present invention include,

vectors containing the nucleic acid segments of interest can

be transferred into the host cell by Well-knoWn methods,

20

Which vary depending on the type of cellular host. For

A puri?ed S. neurona antigen bound to a substrate and a

example, calcium chloride transfection is commonly utilized
for prokaryotic cells, Whereas calcium phosphate treatment
or electroporation may be used for other celluar hosts.
Alternative vectors for the expression of antigen in mam
malian cells can be employed, similar to those developed for

ligand speci?cally reactive With the antigen are also con

templated. Such a puri?ed ligand speci?cally reactive With
the antigen can be an antibody. The antibody can be a
25

the expression of human gammainterferon, tissue plasmino
gen activator, clotting Factor VIII, hepatitis B virus surface

antigen, protease Nexinl, and eosinophil major basic protein.
Further, the vector can include CMV promoter sequences

30

and a polyadenylation signal available for expression of
inserted nucleic acid in mammalian cells (such as COS7).

by a hybridoma cell line speci?cally produced for that
purpose (HarloW and Lane, 1988). Likewise, nonhuman
polyclonal antibodies speci?cally reactive With the antigen
are Within the scope of the present invention. The polyclonal
antibody can also be obtained by the standard immunization

The present invention provides a method of detecting the

the sequences have been operably linked to, i.e., positioned
35

These expression vectors are typically replicable in the host

presence of S. neurona in a subject, comprising the steps of

contacting an antibody-containing sample from the subject
With a detectable amount of the antigenic polypeptide frag
ment of the present invention and detecting the reaction of

organisms either as episomes or as an integral part of the
host chromosomal DNA. Commonly, expression vectors can

the fragment and the antibody, the reaction indicating the

contain selection markers, e.g., tetracycline resistance or

hygromycin resistance, to pennit detection and/or selection

monoclonal antibody obtained by standard methods and as
described herein. The monoclonal antibody can be secreted

and puri?cation protocols (HarloW and Lane, 1988).

The nucleic acid sequences can be expressed in hosts after

to ensure the functioning of, an expression control sequence.

but are not limited to ?uorescent, enzymatic and radioactive
markers.

40

presence of the S. neurona or a previous infection With S.

of those cells transformed With the desired nucleic acid

neurona.

sequences (see, e.g., US. Pat. No. 4,704,362).
Polynucleotides encoding a variant polypeptide may
include sequences that facilitate transcription (expression
sequences) and translation of the coding sequences such that

45

One example of the method of detecting S. neurona is
performed by contacting a ?uid or tissue sample from the
subject With an amount of a puri?ed antibody speci?cally
reactive With the antigen as de?ned herein, and detecting the
reaction of the ligand With the antigen. It is contemplated
that the antigen Will be on intact cells containing the antigen,
or Will be fragments of the antigen. As contemplated herein,
the antibody includes any ligand Which binds the antigen, for

50

example, an intact antibody, a fragment of an antibody or

the encoded polypeptide product is produced. Construction
of such polynucleotides is Well knoWn in the art. For
example, such polynucleotides can include a promoter, a

transcription termination site (polyadenylation site in

eukaryotic expression, hosts), a ribosome binding site, and,
hosts, and, optionally, sequences necessary for replication of

another reagent that has reactivity With the antigen. The ?uid
sample of this method can comprise any body ?uid Which

a vector.

Would contain the antigen or a cell containing the antigen,

optionally, an enhancer for use in eukaryotic expression

rus vector constructs, for example, as set forth in US. Pat.

such as blood, plasma, serum, cerebrospinal ?uid, saliva,
feces and urine. Other possible examples of body ?uids
include sputum, mucus, gastric juice and the like.

Nos. 5,643,576; 5,843,723; 6,156,558; and 6,242,259, the
teachings of Which are hereby incorporated herein by ref

Enzyme immunoassays such as immuno?uorescence
assays (IFA), enzyme linked immunosorbent assays

One presently preferred vector system for expression of
the peptides of the invention comprises the use of Alphavi

55

erence.

A puri?ed monoclonal antibody speci?cally reactive With

60

S. neurona is also provided. The antibodies can be speci?

cally reactive With a unique epitope of the antigen or they
can also react With epitopes of other organisms. The term
“reactive” means capable of binding or otherWise associat
ing non randomly With an antigen. “Speci?cally reactive” as
used herein refers to an antibody or other ligand that does
not cross react substantially With any antigen other than the

65

(ELISA) and immunoblotting can be readily adapted to
accomplish the detection of the antigen. An ELISA method
effective for the detection of the antigen can, for example, be
as folloWs: (1) bind the antibody to a substrate; (2) contact
the bound antibody With a ?uid or tissue sample containing
the antigen; (3) contact the above With a secondary antibody
bound to a detectable moiety (e.g., horseradish peroxidase
enzyme or alkaline phosphatase enzyme); (4) contact the
above With the substrate for the enzyme; (5) contact the

US 7,256,282 B2
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above With a color reagent; (6) observe color change. The

from the list above or other suitable examples by the
standard criteria applied to such selections (HarloW and

above method can be readily modi?ed to detect antibody as
Well as antigen.
Another immunologic technique that can be useful in the

Lane, 1988).
The antigen, e.g., a puri?ed antigenic polypeptide frag

detection of S. neurona or previous S. neurona infection 5

ment encoded by the Sequence Listing of this invention can

utiliZes monoclonal antibodies (MAbs) for detection of
antibodies speci?cally reactive With S. neurona antigen.
Brie?y, sera or other body ?uids from the subject is reacted

be used in the construction of a vaccme comprising an

With the antigen bound to a substrate (e. g. an ELISA 96-Well
plate). Excess sera is thoroughly Washed aWay. A labeled

antigen on an intact S. neurona organism, E. coli or other

immunogenic mount of the antigen and a pharmaceutically
acceptable carrier. The vaccine can be the entire antigen, the
strain, or an epitope speci?c to the antigen. The vaccine can
also be potentially cross-reactive With antibodies to other

(enzyme-linked, ?uorescent, radioactive, etc.) monoclonal
antibody is then reacted With the previously reacted antigen

antigens. The vaccine can then be used in a method of
preventing EPM or other complications of S. neurona infec
tion.
Immunogenic amounts of the antigen can be determined

serum antibody complex. The amount of inhibition of mono

clonal antibody binding is measured relative to a control (no

patient serum antibody). The degree of monoclonal antibody

using standard procedures. Brie?y, various concentrations of
a putative speci?c immunoreactive epitope are prepared,

inhibition is a very speci?c test for a particular variety or

strain since it is based on monoclonal antibody binding
speci?city. MAbs can also be used for detection directly in

administered to an animal and the immunological response

cells by IFA.
A micro-agglutination test can also be used to detect the

20

The pharmaceutically acceptable carrier can comprise
saline or other suitable carriers (Arnon, R. (Ed.) Synthetic

presence of S. neurona in a subject. Brie?y, latex beads (or
red blood cells) are coated With the antigen and mixed With
a sample from the subject, such that antibodies in the tissue
or body ?uids that are speci?cally reactive With the antigen

crosslink With the antigen, causing agglutination. The agglu

Vaccines I: 83-92, CRC Press, Inc., Boca Raton, Fla., 1987).
An adjuvant can also be a part of the carrier of the vaccine,
25

tinated antigen-antibody complexes form a precipitate, vis
ible With the naked eye or capable of being detected by a
spectrophotometer. In a modi?cation of the above test,
antibodies speci?cally reactive With the antigen can be
bound to the beads and antigen in the tissue or body ?uid

(e.g., the production of antibodies) of an animal to each
concentration is determined.

in Which case it can be selected by standard criteria based on

the antigen used, the mode of administration and the subject
(Arnon, R. (Ed.), 1987). Methods of administration can be
by oral or sublingual means, or by injection, depending on
the particular vaccine used and the subject to Whom it is

In addition, as in a typical sandwich assay, the antibody

administered.
It can be appreciated from the above that the vaccine can
be used as a prophylactic or a therapeutic modality. Thus, the

can be bound to a substrate and reacted With the antigen.

invention provides methods of preventing or treating S.

30

thereby detected.
Thereafter, a secondary labeled antibody is bound to
epitopes not recogniZed by the ?rst antibody and the sec

35

ondary antibody is detected. Since the present invention
provides S. neurona antigen for the detection of infectious,

neurona infection and the associated diseases by adminis
tering the vaccine to a subject.
Nucleic acid vaccines against S. neurona are also con

templated by the invention. The antigenic agent for use in

40

the vaccines of the invention can be any nucleic acid, e.g.,
as set forth in the Sequence Listing, that can stimulate an
immune response against, e.g., SnSAG2, SnSAG3 or
SnSAG4 When administered to a subject. Suitable nucleic
acids include those that encode the native proteins of S.

45

speci?c for the antigen (the primary antibody) Will speci?

variant or antigenic peptide fragment thereof., such as, e.g.,
the nucleic acid set forth in the Sequence listing as SEQ ID
NO:23, SEQ ID NO:25 or SEQ ID NO:27. The nucleic acid

cally react With the bound antigen. Thereafter, a secondary

used as a vaccine can be e.g., a naked DNA, or the nucleic

S. neurona or previous S. neurona infection other serological

methods such as ?oW cytometry and immunoprecipitation
can also be used as detection methods.

In the diagnostic methods taught herein, the antigen can
be bound to a substrate and contacted by a ?uid sample such

as serum, cerebrospinal ?uid, urine, saliva, feces or gastric
juice. This sample can be taken directly from the patient or
in a partially puri?ed form. In this manner, antibodies

neurona, e.g., SnSAG2, SnSAG3 or SnSAG4 protein or a

antibody bound to, or labeled With, a detectable moiety can

acid can be incorporated in an expression vector as set forth

be added to enhance the detection of the primary antibody.
Generally, the secondary antibody or other ligand Which is
reactive, either speci?cally With a different epitope of the
antigen or nonspeci?c ally With, the ligand or reacted
antibody, Will be selected for its ability to react With multiple
sites on the primary antibody. Thus, for example, several
molecules of the secondary antibody can react With each

herein, e.g., in an Alpha virus vector (see, e.g., Rosenberg,
50

S. A., Immunity 10:281, 1999).
The presence of S. neurona can also be determined by

detecting the presence of a nucleic acid speci?c for S.

55

neurona or the antigens of S. neurona encoded by the nucleic
acids set forth herein. The present invention provides a
method of detecting the presence of S. neurona in a subject,

primary antibody, making the primary antibody more detect

comprising detecting the presence of the nucleic acid encod

able.
The detectable moiety Will alloW visual detection of a
precipitate or a color change, visual detection by micros
copy, or automated detection by spectrometry, radiometric
measurement or the like. Examples of detectable moieties
include ?uorescein and rhodamine (for ?uorescence micros

ing an S. neurona antigen. As set forth more fully in the

examples beloW, the speci?city of these sequences for S.
neurona can be determined by conducting a computeriZed
60

Word Search or FASTA of the Genetics Computer Group

copy), horseradish peroxidase (for either light or electron

(Madison, Wis.), Which search the catalogued nucleotide

microscopy and biochemical detection), biotin-streptavidin
(for light or electron incroscopy) and alkaline phosphatase
(for biochemical detection by color change). The detection
methods and moieties used can be selected, for example,

comparison With knoWn sequences, catalogued in GenBank,
a computeriZed database, using the computer programs

65

sequences for similarities to the nucleic acid in question.
The nucleic acid speci?c for S. neurona antigen can be

detected utiliZing a nucleic acid ampli?cation technique,
such as polymerase chain reaction or ligase chain reaction.
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Alternatively, the nucleic acid is detected utilizing direct
hybridization or by utilizing a restriction fragment length

containing S. neurona, is digested With a restriction endo

nuclease, and subsequently separated on the basis of size by
agarose gel electrophoresis. The Southern blot technique can
then be used to detect, by hybridization With labeled probes,
the products of endonuclease digestion. The patterns

polymorphism. For example, the present invention provides
a method of detecting the presence of S. neurona comprising
ascertaining the presence of a nucleotide sequence associ
ated With a restriction endonuclease cleavage site. In addi

obtained from the Southern blot can then be compared.
Using such an approach, S. neurona nucleic acid is detected

tion, PCR primers Which hybridize only With nucleic acids

and their mobility on the gel by determining the number of
bands detected and comparing this pattern to the nucleic acid

speci?c for S. neurona can be utilized. The presence of
ampli?cation indicates the presence of S. neurona sequence.
In another embodiment a restriction fragment of a nucleic

from S. neurona.

acid sample can be sequenced directly using, techniques

Similar creation of additional restriction sites by nucle

knoWn in the art and described herein and compared to the

otide substitutions at the disclosed mutation sites can be

knoWn unique sequence to detect S. neurona. In a further

readily calculated by reference to the genetic code and a list
of nucleotide sequences recognized by restriction endonu

embodiment, the present invention provides a method of
detecting the presence of S. neurona by selective ampli?
cation by the methods described herein. In yet another
embodiment S. neurona can be detected by directly hybrid

cleases. Single strand conformational analysis (SSCA)
offers a relatively quick method of detecting sequence
changes Which may be appropriate in at least some
instances.
In general, primers for PCR and LCR are usually about 20

izing the unique sequence With a S. neurona selective

nucleic acid probe. Furthermore, the nucleotide sequence
could be ampli?ed prior to hybridization by the methods

20

described above.
Alternative probing techniques, such as ligase chain reac

Better ampli?cation is obtained When both primers are the
same length and With roughly the same nucleotide compo
sition. Denaturation of strands usually takes place at about
94.degree. C. and extension from the primers is usually at

tion (LCR), involve the use of mismatch probes, i.e., probes
Which are fully complementary With the target except at the
point of the mutation. The target sequence is then alloWed to

hybridize both With oligonucleotides Which are fully
complementary and have oligonucleotides containing a mis
match, under conditions Which Will distinguish betWeen the
tWo. By manipulating the reaction conditions, it is possible
to obtain hybridization only Where there is full complemen
tarity. If a mismatch is present there is signi?cantly reduced

25
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PCR ampli?cation of speci?c alleles (PASA) is a rapid
method of detecting single-base mutations or polymor
phisms. PASA (also knoWn as allele speci?c ampli?cation)
involves ampli?cation With tWo oligonucleotide primers

35

ciently ampli?ed, While the other allele(s) is poorly ampli

The polymerase chain reaction (PCR) and reverse tran

leads to exponential increases in the concentration of desired
nucleic acid sequences. Given a knowledge of the nucleotide
sequence of S. neurona as set forth herein, synthetic oligo
nucleotides can be prepared Which are complementary to
sequences Which ?ank the nucleic acid of interest. Each
oligonucleotide is complementary to one of the tWo strands.
The nucleic acid can be denatured at high temperatures (e.g.,

95.degree. C.) and then reannealed in the presence of a large
molar excess of oligonucleotides. The oligonucleotides,
oriented With their 3' ends pointing toWards each other,
hybridize to opposite strands of the target sequence and

such that one is allele-speci?c. The desired allele is e?i
?ed because it mismatches With a base at or near the 3' end

of the allele-speci?c primer. Thus, PASA or the related
method of PAMSA may be used to speci?cally amplify the
mutation sequences of the invention. Where such ampli?
40

successfully detect a single-base substitution. LCR probes
45

may be combined or multiplexed for simultaneously screen

ing for multiple different mutations. Thus, LCR can be
particularly useful Where, as here, multiple mutations are
50

ampli?cation of a nucleic acid segment by more than one
million-fold can be achieved. The resulting nucleic acid may

then be directly sequenced.
In yet another method, PCR may be folloWed by restric

cation is done on S. neurona isolates or samples obtained
from an individual, it can serve as a method of detecting the
presence of S. neurona. As mentioned above, a method

knoWn as ligase chain reaction (LCR) can be used to

prime enzymatic extension along the nucleic acid template.
The end product is then denatured again for another cycle.
After this three-step cycle has been repeated several times,

about 72.degree. C. The annealing temperature varies
according to the sequence under investigation. Examples of
reaction times are: 20 mins denaturing; 35 cycles of 2 min,
1 min, 1 min for annealing, extension and denaturation; and
?nally a 5 min extension step.

hybridization.
scriptase PCR are techniques that amplify speci?c nucleic
acid sequences With remarkable e?iciency. Repeated cycles
of denaturation, primer annealing and extension carried out
With polymerase; e.g., a heat stable enzyme Taq polymerase,

bp in length and the preferable range is from 15-25 hp.

predictive of the same disease.
The present invention is more particularly described in the
folloWing examples Which are intended as illustrative only,
since numerous modi?cations and variations therein Will be
apparent to those skilled in the art.
EXAMPLES
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tion endonuclease digestion With subsequent analysis of the
Identi?cation and Characterization of SnSAGl

resultant products. Nucleotide substitutions can result in the
gain or loss of speci?c restriction endonuclease sites. The
gain or loss of a restriction endonuclease recognition site

facilitates the detection of the organism using restriction

Surface biotinylation of extracellular merozoites revealed
only tWo dominant labeled molecules that migrate at about
60

30 kDa and 16 kDa in SDS-PAGE. Analysis of a S. neurona

fragment length polymorphism (RFLP) analysis or by detec

EST database (currently 1800+ sequences) identi?ed an

tion of the presence or absence of a polymorphic restriction
endonuclease site in a PCR product that spans the sequence
of interest.

orthologue of the 31-kDa surface antigen from Sarcocyslis

For RFLP analysis, nucleic acid is obtained, for example

from the blood, cerebrospinal ?uid, gastric specimen, saliva,
dental plaque, other bodily ?uids of the subject suspected of

muris. The sequence of the S. neurona surface antigen gene,

designated SnSAGl, is predicted to encode a 276-residue
65

protein With an amino-terminal signal peptide and a car

boxy-terminal GPI anchor addition. Antiserum raised
against recombinant SnSAGl recognized a 25-kDa antigen
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in Western blots of non-reduced S. neurona lysates, consis

sarco/index.html) using the BLAST (basic local alignment

tent With the molecular Weight predicted for the mature

search tool) set of programs [Altschul, 1990 #616]. At the

SnSAGl. Under reducing conditions, SnSAGl migrated
aberrantly at about 30 kDa, similar to What has been
observed in Western blot analyses of reduced T gondii

time the database Was searched, it contained 686 consensus
sequences that had been generated from 1883 S. neurona
ESTs. Selected cDNAs Were obtained from the archived

surface antigens. lmmuno?uorescence labeling of SnSAGl

collection of EST clones and sequenced using ABI Prism

during intracellular groWth of S. neurona indicated that the

BigDye Terminator Cycle Sequencing reaction mix (Perkin

protein is expressed throughout schiZogony. Interestingly, a

Elmer Applied Biosystems). The reactions Were puri?ed

?lamentous staining pattern Was observed in intermediate
schiZonts that likely re?ects localiZation of the surface

using Centri-Sep spin columns (Princeton Separations), and

antigen to previously-described invaginations of the sch

the eluted extension products Were resolved and analyZed on
an ABI 310 Genetic AnalyZer. Sequence analyses Were

iZont surface membrane.

conducted With Genetics Computer Group (GCG) softWare

Parasite Culture
S. neurona strain SN3 [Granstrom, 1992 #1600] mero
Zoites Were propagated by serial passage in bovine turbinate

National Center for Biotechnology Information (NCBI) Web
site (See, e.g., WWW.ncbi.nlm.nih.gov/) and the Expert Pro
tein Analysis System (ExPASy) server of the SWiss Institute

[Devereux, 1984 #1176] and programs available on the

(BT) cells and maintained in RPMI 1640 medium supple

of Bioinformatics (See, e.g., WWW.expasy.ch/). Multiple

mented With 10% fetal bovine serum, 2 mM sodium pyru

vate, Pen/Strep FungiZone (BioWhittaker, Inc.). Extracellu
lar meroZoites Were harvested and puri?ed from disrupted
host cell monolayers by ?ltration through 3.0 pm mem
branes, as described previously for Neospora caninum

20

AY032845.

Recombinant SnSAGl Expression and Generation of Poly

[HoWe, 1997 #1372].
Immunoscreen of S. neurona cDNA Library
Construction and analyses of the cSn.1 S. neurona mero

sequence alignments Were performed using Multalin soft
Ware [Corpet, 1988 #2046]. The sequence reported herein
has been deposited into GenBank under accession number

clonal Antiserum

The SnSAGl open reading frame Without the predicted
25

amino-terminal signal peptide and the carboxyl-terminal

Zoite cDNA library has been described previously [HoWe,

hydrophobic tail Was ampli?ed by PCR from the pSnAg8

2001 #1787]. The library Was plaqued for 3 hrs at 420 C. on
XLl-Blue MRF’ E. coli host cells (Stratagene) groWn on

cDNA using primers that introduce a NdeI restriction site
prior to base 45 (numbered from the initiation codon) and an
XhoI site after base 743. The ampli?cation product Was

150 mm NZY agar plates. When plaques became visible,
plates Were overlayed With nitrocellulose ?lters previously
soaked in 10 mM isopropyl-[3-D-thiogalactopyranoside

30

(IPTG) for an additional 3 hr incubation at 370 C. Filters
Were lifted from the plates, Washed With TNT buffer (10 mM

Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% TWeen 20), and
blocked in phosphate buffered saline (PBS), 5% dry milk,

35

5% normal goat serum, 0.05% TWeen 20.

by nickel-column chromatography according to the manu

facturer’s protocol (Novagen), and monospeci?c polyclonal
antisera Were produced against the puri?ed protein by
40

45

After adsorption of potential cross-reactive antibodies, the

membranes by semidry electrophoretic transfer. in Tris
50

1:10,000. Immuno-reactive phage plaques Were picked With
sterile pipet tips and suspended in 40 ul of SM buffer (50
mM Tris-HCl, pH 7.5, 100 mM NaCl, 8 mM MgSO4, 0.01%
gelatin). The cDNA inserts Were PCR ampli?ed using the T3

ImmobiliZed Streptavidin
60

Approximately 3><107 freshly harvested meroZoites Were
resuspended in 1 ml cold PBS (pH 7.8). Sulfo-N-hydroxy
succinimide-biotin (Pierce) Was added to a concentration of

S. neurona EST Database Searches and Sequence Analyses

clustered EST database (See, e.g., paradb.cis.upenn.edu/

Immunoresearch Labs, Inc.). Blots Were Washed, processed
for chemiluminescence using Supersignal substrate (Pierce
Chemical Company), and exposed to ?lm.
Biotinylation of Surface Proteins and Precipitation With

cells according to the manufacturer’s protocol (Stratagene).
S. neurona homologues to previously-characterized coc
cidian surface antigens Were identi?ed in the S. neurona

glycine buffer (pH 8.3). Membranes Were blocked With PBS
containing 5% nonfat dry milk, 5% goat serum, and 0.05%
TWeen 20, and then incubated for 1 hr With primary anti
body. After Washing, membranes Were incubated With HRP

conjugated immunoglobulin G secondary antibody (Jackson
55

and T7 oligonucleotide primers, and the resulting products
Were analyZed by agarose gel electrophoresis. Sequencing
reactions using T3 primer Were conducted on the ampli?ed
cDNAs to provide a preliminary identi?cation of the immu
noreactive clones. Phagemid excision Was performed on
selected cDNA clones, and plasmids Were rescued in SOLR

Western Blot Analysis
Parasites Were lysed in sodium dodecyl sulfate (SDS)
sample buffer supplemented With protease inhibitor cocktail
(Sigma) and 2% 2-mercaptoethanol, and the lysates Were
separated in 10% or 12% polyacrylamide gels [Laemmli,
1970 #393]. Proteins Were transferred to nitrocellulose

diluted CSF solution Was incubated for 1 hr With the cSn.1
?lters. After Washing, ?lters Were incubated for 1 hr With

goat anti-equine IgG conjugated to horseradish peroxidase
(HRP) (Jackson Immunoresearch Labs, Inc.) diluted to

immunization of a rabbit and rat (Cocalico Biologicals,

Inc.).

?lters carrying plaque lifts of a previously-described N.
caninum cDNA library [HoWe, 1999 #1759] to remove
antibodies that Were reactive With E. coli and phage proteins.

mid, designated prSnSAG1, Was transformed into BL21
CodonPlus E. coli (Stratagene), and a clone that expressed
high levels of recombinant SnSAGl (rSnSAGl) Was
selected for use. The histidine-tagged rSnSAG1 Was puri?ed

Antigenic cDNA clones Were identi?ed by screening With
cerebrospinal ?uid (CSF) from a horse that had been natu
rally infected With S. neurona and exhibited a high titer of
intrathecal antibodies against S. neurona in Western blot
analysis. Prior to screening the S. neurona cDNA library, the
CSF Was diluted 1:20 in PBS, 0.1% dry milk, 0.1% normal
goat serum, 0.05% TWeen 20 and incubated for 30 min With

digested With NdeI and XhoI, ligated into NdeI/XhoI-di
gested pET22b expression vector (Novagen), and trans
formed into INVotF’ E. coli. The resulting expression plas

65

0.5 mg/ml and incubated at room temperature for 30 min.
The labeled parasites Were Washed tWice With 5 ml of PBS
and stored at —200 C.

The labeled parasite pellet Was lysed With 1 ml radio

immunoprecipitation assay (RIPA) buffer (50 mM Tris [pH
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7.5], 1% Triton X-100, 0.5% sodium deoxycholate, 0.2%
SDS, 100 mM NaCl, 5 mM EDTA) supplemented With

the carboxyl terminus (data not shoWn). The signal peptide
cleavage is predicted to occur at Alals-Argl6 (SignalP;
[Nielsen, 1997 #2047], and the most likely GPI transami
dase cleavage site is predicted to be at Ala247-Asn248 (DGPI;
SWiss Institute of Bioinformatics). A single N-glycosylation

RNase, DNase, protease inhibitor cocktail, and the sample
Was centrifuged at 16,000><g to remove the insoluble frac
tion. The soluble proteins Were incubated With UltraLink

immobilized streptavidin (Pierce), and the precipitated

site Was predicted at residues 140-143. Removal of the
N-terminal and C-terminal signal sequences results in a
mature protein of 242 amino acids that has a predicted

biotin-labeled protein fraction Was analyzed by Western
blotting, as described above.

molecular Weight of 24.2 kDa before any potential post

lmmuno?uorescent Labeling of Extracellular and Intracel
lular Parasites

translational modi?cations (e.g., glycolipid anchor addition,

glycosylation).

For detection of SnSAGl on extracellular parasites and in

To identify homology to previously characterized

trails deposited by gliding parasites, freshly lysed merozoi

sequences, BLAST searches [Altschul, 1990 #616] of the

tes Were suspended in fresh RPMI 1640 and incubated on

non-redundant GenBank databases Were conducted With the

poly-L-lysine-coated slides for approximately 30 min.

SnAgI.8 coding sequence as the query. These searches
revealed a statistically signi?cant similarity to the 31 kDa

Slides Were Washed With PBS, and the parasites Were ?xed

in 2.5% formalin-PBS containing 0.01% glutaraldehyde. For

major surface antigen of Sarcocyslis muris [Eschenbacher,

detection of SnSAGl on intracellular parasites, merozoites

1992 #1767] and a less signi?cant but recognizable simi
larity to several SAG2-related surface antigens from T

Were inoculated onto BT cells groWn on LabTek chamber

slides (Nunc). At 24 hr, 48 hr, or 72 hr post-inoculation, the
cells Were ?xed in 2.5% formalin-PBS/0.01% glutaralde

20

the Western blot analysis and the predictions of a signal
peptide and a GPI-anchor addition, these results suggested

hyde and per'meablized With 0.2% TritonX-100. After incu
bation With primary antibody, the slides Were rinsed, then
incubated With ?uorescein isothiocyanate (FITC)-conju

gated goat anti-rabbit IgG (Jackson Immunoresearch Labs,
Inc.). The slides Were mounted in Vectashield With DAPI

that the gene represented by the SnAgI.8 and SnAgI.9
cDNAs encodes an immunodominant surface antigen of S.
25

neurona; consequently, We tentatively designated this pro
tein SnSAGl, folloWing the genetic nomenclature that is
utilized for the related apicomplexan parasites T gondii and
N. caninum [Sibley, 1991 #13; HoWe, 1999 #1759].
The sequence analysis for SnSAG2, SnSAG3; and

30

SnSAG4 as Well as for the SnGF Cluster sequences provided
by the invention and set forth herein have been derived in a
fashion similar to that set forth above for SnSAGl. These
novel nucleotide sequences and protein sequences of Sar
cocyslis neurona can be utilized in the production of vac

(Vector Laboratories, Inc.) and examined With a Zeiss axio

scope equipped for epi?uorescence microscopy.
Results

Isolation and Analysis of Immunoreactive cDNA Clones
A primary screen of the cSn.1 cDNA library identi?ed
multiple immunoreactive phage plaques, and a total of 25
plaques Were isolated and resuspended in SM bulfer. Ampli
?cation of the cDNA inserts With T3 and T7 oligonucle
otides revealed that 22 of the phage clones had similar

35

cines and/or antigen/antibody kits for prevention and diag
nosis of Sarcocyslis neurona infection. One preferred

lengths of approximately 1500 base pairs (bp), and sequence
analysis using T3 primer indicated that these 22 cDNAs
represent the same gene. A secondary screen Was performed
on ?ve of the selected cDNAs, and tWo highly reactive

gondii [Lekutis, 2000 #2049]. (FIG. 2). In conjunction With

embodiment of the invention is a vaccine comprised of an

alpha virus expression vector and nucleic acid selected from
the nucleic acid sequences disclosed herein.
40

phage clones, designated SnAgI.8 and SnAgI.9, Were chosen
for further analyses.

Identi?cation. of S. neurona Surface Antigens and Expres
sion as Recombinant Proteins

To obtain a preliminary identi?cation of the parasite

Analysis of the S. neurona EST database revealed four

protein encoded by the selected cDNAs, the SnAgI.9 clone

paralogous proteins that are homologous to the SAG and
SRS surface antigens of Toxoplasma gondii. Each S. neu

Was used to a?inity purify antibodies that bind the antigen
expressed by this clone, and the eluted antibodies Were used

45

rona gene Was predicted to encode a protein that possessed

to probe a Western blot of S. neurona merozoite lysate. As

an amino-terminal signal peptide and a carboxyl-tenninal

shoWn in FIG. 1, the puri?ed antibodies reacted With an
approximately 31-kDa antigen in reduced S. neurona lysate.

glycolipid anchor site, consistent With the proteins being
surface antigens. Because of their similarity to Toxoplasma

Furthermore, the antigen revealed by the phage-puri?ed

50

antibodies comigrated With a protein that is recognized by

SAGs and their probable surface display on merozoites, the
four S. neurona proteins Were designated SnSAGl,

equine or rabbit antisera against S. neurona as the major

SnSAG2, SnSAG3, and SnSAG4. The four putative surface

immunodominant antigen of this parasite (FIG. 1, lanes 2
and 3). This result implies that the 22 matching cDNA clones
isolated during the library screen and represented by
SnAgI.8 and SnAgI.9 encode the immunodominant antigen

antigens Were each expressed as a recombinant protein in E.
coli, and these Were used to immunize rabbits and rats for
55

of S. neurona.

Full-length sequence analysis of SnAgI.8 revealed a
cDNA insert of 1493 nucleotides, With an open reading
frame (ORF) that encodes a 276 amino acid protein.
Sequence analysis of SnAgI.9 indicated that this clone Was

virtually identical to SnAgI.8, although its 3' untranslated
region (UTR) Was approximately 160 nucleotides longer due
to an alternative polyadenylation site. A hydrophobicity plot
of the encoded protein shoWed hydrophobic domains at both
termini, Which correspond to a predicted signal peptide at
the amino terminus and a GPI anchor addition sequence at

monospeci?c polyclonal antisera production. The resulting
polyclonal antisera Were used in Western blot analysis of
reduced (With 2-mercaptoethanol) S. neurona lysate to
reveal each of the SnSAGs (See, FIG. 3). The mature forms
of native SnSAGl and SnSAG4 are predicted to be approxi
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mately 24 kDa, but these antigens co-migrated at approxi
mately 30-32 kDa and correspond to the immunodominant
antigen Sn30 that has been described previously (See, FIG.

3) (Granstrom et al., 1993; Liang et al., 1998). SnSAGl has
also been identi?ed by others as a major surface antigen
65

matching the immunodominant Sn30 band (Ellison et al.,
2002), but it is apparent that SnSAG4 likely contributes to
the antibody reactivity at this molecular Weight. The mature
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form of SnSAG2 is predicted to be about 12 kDa, but this
antigen migrated at approximately 18-19 kDa and corre
sponds to the previously described immunodominant Sn16

?nal protein concentrations of 8.15 pg/ml, 23.0 pg/ml, 14.56

antigen (See, FIG. 3) (Granstrom et al., 1993; Liang et al.,

horses With histologically con?rmed EPM. The negative

1998). Mature SnSAG3 is predicted to be 23 kDa, but
migrated at about 28 kDa (See, FIG. 3). The aberrant
migration of the SnSAGs under reducing conditions is a
characteristic that has been observed previously for the
surface antigens of both T gondii (Burg et al., 1988;
Cesbron-DelauW et al., 1994) and N. caninum (HoWe et al.,
1998). Importantly, the Western blot experiments demon

control sample for all assays Was a preinfection serum

pg/ml, and 10.3 pg/ml, respectively.
Positive control serum samples Were obtained from tWo

sample from a Weanling used in an experimental infection
trial. Thirty six equine serum samples submitted for S.
neurona serology testing Were used for standardiZation of

the rSnSAG ELISAs. The samples had previously been
classi?ed as positive or negative by Western blot. TWenty
seven samples from horses of con?rmed EPM status Were

recogniZed by antibodies from S. neurona-infected horses.
There is strong concordance betWeen antibody recognition

obtained from a collection of the University of Kentucky
Gluck Equine Research Center. All cases Were con?rmed by
histological examination of central nervous system tissues

of recombinant SnSAGl (rSnSAGl) and standard Western

for the presence of lesions consistent With EPM, as Well as

blot analysis of complete parasite antigen (i.e., S. neurona

Western blot analysis of CSF ?uids. Three equine serum
samples from an S. fayeri challenge trial Were used to
examine assay cross-reactivity. An N. hughesi positive con

strated that the recombinant forms of the SnSAGs are

meroZoite lysate). Similar results Were obtained With rSn

SAG2, rSnSAG3, and rSnSAG4. These data demonstrate
the utility of using the rSnSAGs in ELISA formats to
monitor antibody responses in S. neurona-infected horses.

trol serum sample Was also evaluated.
20

EnZyme-Linked Immunosorbent Assays (ELISAs) Based on
Recombinant S. neurona Surface Antigens (rSnSAGs)
The rSnSAGs expressed in E. coli have been shoWn in
Western blots to be recogniZed by equine antibodies; con
sequently, these recombinant antigens can be utiliZed as the
key reagents for developing ELISAs based on single S.

Western blot, proteins Were transferred to nitrocellulose
25

20, and 5% normal goat serum, and incubated for 1 hour in

neurona antigens. An ELISA test Was developed for each of

oxidase-conjugated secondary antibodies (Jackson Immu
30

To produce highly puri?ed recombinant forms of the
SnSAGs, the genes for each antigen Were cloned into the

pET22b expression plasmid from Novagen (Madison, Wis.).
This plasmid vector provides a carboxyl-terminal fusion to
a 6-residue oligohistidine domain (His-Tag), Which binds to
metal ion af?nity columns and alloWs for the ef?cient

noResearch Laboratories, Inc.). Membranes Were processed
for chemiluminescent detection using SuperSignal substrate
(Pierce) and exposed to radiographic ?lm or documented
With a FluorChem 8800 imaging system (Alpha Innotech

Corp.).
35

For rSnSAS ELISAs, high-binding 96-Well plates (Com
ing) Were incubated overnight at 40 C. With 100 pl puri?ed
rSnSAGl, rSnSAG2, rSnSAG3, or rSnSAG4 diluted to 0.20

one-step puri?cation of the expressed recombinant protein.

pg/ml, 1.00 pg/ml, 0.09 pg/ml, and 0.21 pg/ml, respectively.

Plasmid constructs Were transformed into BL21 (DE3) host

cells (CodonPlus, Stratagene, Inc.), and expression of
recombinant protein Was induced by addition of IPTG.

membranes by semi-dry electrophoresis. Membranes Were
blocked With PBS containing nonfat dry milk, 0.1% TWeen
primary antibody solution. The membranes Were Washed,
folloWed by incubation for 45 min. With horseradish per

the four rSnSAGs that have been identi?ed by the invention.

Expression and Puri?cation of Recombinant SnSAGs.

Native and recombinant proteins Were suspended in SDS
PAGE buffer supplemented With protease inhibitor cocktail
(Sigma) and separated on 12% polyacrylamide gels. For

40

The plates Were rinsed With PBS/0.05% TWeen 20 and
blocked for 1.5 h at room temperature With PBS/ 1% TWeen

Bacterial clones that reliably expressed the recombinant

20/0.5% normal goat serum/0.001 g/ml nonfat dry milk.

SnSAGs Were selected and cyropreserved for future study.
The recombinant S. neurona surface antigens have been

20/0.5% normal goat serum/0.001 g/ml nonfat dry milk. One

Primary sera or CSF Was diluted With PBS/1% TWeen

designated rSnSAGl, rSnSAG2, rSnSAG3, and rSnSAG4.
To obtain recombinant protein, the appropriate bacterial
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incubated for 2 h at room temperature. The Wells Were

clone Was groWn to logarithmic phase in LB medium, and
protein expression Was induced by addition of IPTG to the
culture. The recombinant protein Was extracted from inclu
sion bodies With 6 M urea and puri?ed from the host cell

lysate by Ni++-column chromatography according to the
manufacturer’s protocol (His-Bind resin and buffers,

rinsed, and then incubated for 2 h at room temperature With

150 pl of horseradish peroxidase-conjugated goat anti-horse

immunoglobulin G (IgG) secondary antibody (Jackson
50

Novagen). Urea Was removed by dialysis. If necessary,
recombinant proteins Was concentrated by centrifugal ultra
?ltration in Centricon-10 columns (Amicon).

ELISA Assay
The SN3 strain of S. neurona and the Oregon strain of

tion, the OD of each sample Was expressed as a percentage
60

Concentration of puri?ed recombinant proteins prepared
as described above Was determined by a calorimetric assay

(Coomassie Plus Protein Assay Reagent, Pierce). Puri?ed

(Sigma) at 0.4 mg/ml (200 pl) Was added. After 10 min
incubation, the reaction Was stopped With 50 pl of 3 M
H2SO4, and OD490 Was measured in an Emu microplate

reader (Molecular Devices). To account for interplate varia

opore membrane ?lter, Whatman) to remove debris. Har
vested parasites Were counted, Washed, and stored at —200 C.

rSnSAGl, rSnSAG2, rSnSAG3, and rSnSAG4 Were diluted
in buffer (0.5 M NaCl and 20 mM Tris-HCl) Without urea to

ImmunoResearch Laboratories, Inc.) diluted to 1:10,000 in
PBS/1% TWeen 20/0.5% normal goat serum/0.001 g/ml
nonfat dry milk. The Wells Were then again rinsed. The

chromogenic substrate o-phenylenediamine dihydrochloride
55

Neospora hughesi Were maintained by serial passage in
bovine turbinate cell monolayers. Upon lysis of the host cell
monolayer, Zoites Were dispersed and ?ltered (3 .0 pm Nucle

hundred pl aliquots of the sera or CSF containing mixed
antibody populations Were added to duplicate Wells and
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of the high positive standard on the plate.
Serum antibody titers against rSnSAG4 Were detected in
25 of 26 (96.2%) EPM-con?rmed horses (see FIG. 6). The
rSnSAG2 and rSnSAG3 ELISAs yielded seropositive
results in 24 of 26 (92.3%) EPM-con?rmed horses. Only 18
of the 26 (69.2%) horses had detectable serum antibody
titers against rSnSAGl. In total, 18 (81.8%), 18 (81.8%), 20
(90.0%), and 21 (95.5%) of the 22 CSF samples had

detectable antibody titers against rSnSAGl, rSnSAG2, rSn

